10x Genomics' Stock Sees Bollinger Bands Narrowing, KDJ Death Cross Triggered

According to the 15-minute chart for 10x Genomics, a narrowing of the Bollinger Bands and a KDJ Death Cross at 07/29/2025 15:45 indicate that the magnitude of stock price fluctuations is decreasing and momentum is shifting towards the downside, suggesting a potential further decline in the stock price.

July 02, 2025

Analysts and investors are closely monitoring the latest developments in the biotech sector, particularly focusing on 10x Genomics Inc. (NASDAQ: TXG). The company's stock has experienced significant volatility following its disappointing third-quarter earnings report, which missed analyst expectations by a substantial margin [1]. As of Thursday, October 10, 2024, 10x Genomics Inc.'s stock has been trading down by -29.7 percent, raising concerns about future profitability and growth prospects.

The recent earnings report revealed that 10x Genomics' Q3 revenue stood at $151.7 million, falling short of the expected $162.24 million. This shortcoming, coupled with a negative EBIT margin of -36.9% and a profit margin of almost -38%, indicates significant challenges in managing costs and research expenses. Despite a strong gross margin of 64.7%, the company's high R&D costs—amounting to over $62.9 million—have been a significant drag on profitability [1].

Adding to these concerns, the current 15-minute chart for 10x Genomics Inc. shows a narrowing of the Bollinger Bands and a KDJ Death Cross at 07/29/2025 15:45. This technical indicator suggests that the magnitude of stock price fluctuations is decreasing, and momentum is shifting towards the downside. Historically, a KDJ Death Cross has signaled a potential reversal in trend, suggesting a further decline in the stock price [2].

Investors and financial analysts are reacting strongly to these figures. The earnings miss has shaken investor confidence, highlighting the unpredictable nature of biotech investments. The company's enterprise value of over $2.13 billion, despite a high priceto-sales ratio of 3.97, underscores the potential for overvaluation [1].

To navigate these challenges, 10x Genomics Inc. must focus on strategic cost management and efficient utilization of research funds. A clear recovery strategy, coupled with effective communication of future plans, will be crucial for regaining investor faith. The broader market sentiment, influenced by emotional responses and numerical figures, will also play a significant role in determining the stock's future trajectory.

In conclusion, while the immediate impact of the Q3 earnings miss is evident, the long-term narrative for 10x Genomics Inc. remains uncertain. The narrowing Bollinger Bands and KDJ Death Cross suggest a potential further decline in stock price, but strategic refinements and effective communication could turn this setback into a stepping stone.

References:
[1] https://www.timothysykes.com/news/10x-genomics-inc-txg-news-2024_10_10/
[2] https://finance.yahoo.com/news/fortrea-azenta-bio-techne-10x-193602941.html